Study register · detail
Clear benefit
GRADE
High
26 citations
Samplek = 14 Studien
n = 203.783 Pat.
n = 203.783 Pat.
Durationunclear
ControlNo prenatal cannabis exposure
EndpointADHD symptoms / ASD risk
Blindingunklar
DesignMeta-Analyse
Key finding
Prenatal cannabis exposure is associated with increased risk of ADHD symptoms and autism spectrum disorder in offspring.
Summary
Systematic review and meta-analysis on prenatal cannabis exposure and neurodevelopmental disorders; k=14 studies (10 on ADHD, 4 on ASD), n=203.783 participants. Prenatal cannabis exposure associated with increased risk of ADHD symptoms (β=0,39; 95% CI 0,20–0,58, I²=66,85%, p=0,001) and diagnosed ADHD (RR=1,13; 95% CI 1,01–1,26) as well as ASD (RR=1,30; 95% CI 1,03–1,64, I²=45,5%, p=0,14) in offspring.
P
PopulationChildren/adolescents whose mothers used cannabis during pregnancy, pooled n=203.783
I
InterventionPrenatal cannabis exposure (in utero)
C
ControlNo prenatal cannabis exposure
O
OutcomeIncreased risk of ADHD symptoms [β=0,39; 95%-CI 0,20–0,58; p=0,001] and ASD [RR=1,30; 95%-CI 1,03–1,64] in exposed offspring
Confidence in the evidence
High
The highest of four GRADE levels, the effect estimate is very reliable.
Quality profile
Sample size
★★★★★
Blinding
—
Effect size
Clear benefit
Citations / year
★★★★★
Authors
Share
Abstract
Background: It is plausible that exposure to cannabis in-utero could be associated with an increased risk of neurodevelopmental disorders such as attention deficit hyperactivity disorder (ADHD) symptoms and autism spectrum disorder (ASD) during childhood and adolescence; however, mixed results have been reported. This study investigated whether there is an association between prenatal cannabis use and ADHD symptoms and ASD in offspring using a systematic review and meta-analysis methodology.
Methods: A systematic literature search was conducted in PubMed/Medline, Scopus, EMBASE, Web of Science, Psych-Info, and Google Scholar to identify relevant studies. The study protocol has been preregistered in the Prospective Register of Systematic Reviews (PROSPERO) (CRD42022345001), and the Newcastle-Ottawa Quality Assessment Scale (NOS) was used to assess the methodological quality of included studies. An inverse variance weighted random effect meta-analysis was conducted to pool the overall effect estimates from the included studies.
Results: Fourteen primary studies, consisting of ten on ADHD and four on ASD, with a total of 203,783 participants, were included in this study. Our meta-analysis underscores an increased risk of ADHD symptoms and/or disorder [beta = 0.39: 95 % CI (0.20-0.58), I(2) = 66.85 %, P = 0.001)] and ASD [RR = 1.30: 95 % CI (1.03-1.64), I(2) = 45.5 %, P = 0.14] associated with in-utero cannabis exposure in offspring compared to their non-exposed counterparts. Additionally, our stratified analysis highlighted an elevated risk of ADHD symptoms [beta = 0.54: 95 % CI (0.26-0.82)] and a marginally significant increase in the risk of diagnostic ADHD among exposed offspring compared to non-exposed counterparts [RR = 1.13, 95 % CI (1.01, 1.26)].
Conclusion: This study indicated that maternal prenatal cannabis exposure is associated with a higher risk of ADHD symptoms and ASD in offspring.
The impediment to action advances action.